论文部分内容阅读
我院于1990年用华西医大药学院研制的盐酸米托恩醌(DHAQ)治疗急性白血病13例、恶性淋巴瘤6例,现将结果报道如下。材料与方法一、病例选择急性白血病13例均经临床、血象、骨髓及细胞化学检查确诊,按FAB分型。单用组6例,1例在治疗过程中因严重感染出血死亡未纳入统计,联用组9例,1例在1疗程完后,病情稳定自动出院未列入统计。恶性淋巴瘤6例均经病理检查确诊,有可测量的客观标准,复治者停用化疗1月以上。
Our hospital in 1990 with the Huaxi Medical College developed mothoquinone hydrochloride (DHAQ) in the treatment of acute leukemia in 13 cases, 6 cases of malignant lymphoma, the results are reported below. Materials and methods A case selection of acute leukemia in 13 cases were clinically, hemogram, bone marrow and cytochemical examination confirmed by FAB typing. In the single group, 6 cases were treated. In the course of treatment, one case died of severe infection and bleeding was not included in the statistics. In combination group, 9 cases were treated, and 1 case was discharged after 1 course of treatment. Malignant lymphoma in 6 cases were confirmed by pathological examination, measurable objective criteria, retreatment chemotherapy discontinued more than January.